Moderate

Thalassaemia - chronic management & monitoring

thalassaemia mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Inherited defects of globin chain synthesis causing ineffective erythropoiesis and haemolysis. Transfusion-dependent thalassaemia requires regular transfusion plus iron chelation; non-transfusion-dependent forms need surveillance for iron loading and complications.

Red flags

  • Cardiac iron overload with arrhythmia or heart failure
  • Rapidly rising ferritin despite chelation
  • Agranulocytosis on deferiprone
  • New endocrine failure (diabetes, hypothyroidism)
  • Post-splenectomy sepsis

Assessment

Differential diagnosis

  • Iron deficiency anaemia
  • Sickle cell / HbE disorders
  • Congenital sideroblastic anaemia
  • Other chronic haemolytic anaemia
  • Myelodysplasia

Investigations

  • FBC and film (microcytosis, target cells, basophilic stippling)
  • Haemoglobin electrophoresis / HPLC and genetic analysis
  • Ferritin, transferrin saturation
  • Liver and cardiac iron by MRI (T2*) in transfusion-dependent disease
  • Endocrine screen (thyroid, glucose, gonadal, parathyroid)
  • Bone densitometry; echocardiography

Management

  • Confirm genotype and classify as transfusion-dependent or non-transfusion-dependent
  • For transfusion-dependent thalassaemia, transfuse regularly to maintain pre-transfusion Hb 95-105 g/L and suppress ineffective erythropoiesis
  • Start iron chelation once iron loading established (after ~10-20 transfusions or ferritin rising)
  • Select chelator (oral deferasirox or deferiprone, or subcutaneous desferrioxamine) and monitor cardiac/hepatic iron by MRI
  • Give folic acid and avoid medicinal iron
  • Screen for and manage endocrinopathy, osteoporosis, cardiac and hepatic complications
  • Vaccinate and consider splenectomy only where clearly indicated (with prophylaxis)
  • Offer luspatercept to reduce transfusion burden in eligible beta-thalassaemia
  • Discuss curative options: allogeneic stem cell transplant and gene therapy
  • Provide genetic counselling and antenatal screening for families

Drugs & doses

Deferasirox 14-28 mg/kg PO once daily (film-coated tablet)
Deferiprone 75-100 mg/kg/day PO in 3 divided doses
Desferrioxamine 20-40 mg/kg SC infusion over 8-12 h, 5-7 nights/week
Folic acid 5 mg PO once daily
Luspatercept 1-1.33 mg/kg SC every 3 weeks (transfusion-dependent beta-thalassaemia)

Disposition

Specialist thalassaemia centre; regular transfusion/chelation clinic and multidisciplinary surveillance.

Complications & pitfalls

  • Iron-overload cardiomyopathy (leading cause of death)
  • Hepatic fibrosis/cirrhosis
  • Endocrinopathy and osteoporosis
  • Extramedullary haematopoiesis
  • Alloimmunisation and transfusion reactions
  • Deferiprone agranulocytosis

Exam pearls

  • Cardiac T2* MRI detects iron loading before symptoms and guides intensified chelation
  • Pre-transfusion Hb target around 100 g/L suppresses marrow drive and extramedullary haematopoiesis
  • Weekly FBC monitoring is essential on deferiprone (agranulocytosis risk)
  • Never give oral iron to a thalassaemic patient
  • Luspatercept and gene therapy are reshaping transfusion-dependent care

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.